# Evolution of CMV Antiviral T-cell Immunity Over the Next Six Months Initiation of Treatment With Belatacept.

> **NCT05708534** · — · RECRUITING · sponsor: **University Hospital, Rouen** · enrollment: 28 (estimated)

## Conditions studied

- Kidney Transplant Infection

## Interventions

- **DRUG:** Belatacept

## Key facts

- **NCT ID:** NCT05708534
- **Lead sponsor:** University Hospital, Rouen
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2023-11-14
- **Primary completion:** 2026-09-01
- **Final completion:** 2026-12-31
- **Target enrollment:** 28 (ESTIMATED)
- **Last updated:** 2025-06-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05708534

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05708534, "Evolution of CMV Antiviral T-cell Immunity Over the Next Six Months Initiation of Treatment With Belatacept.". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT05708534. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*